Side-by-side · Research reference

MatrixylvsVIP

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED9/39 cited

BPhase 3HUMAN-REVIEWED9/42 cited

Matrixyl

Cosmeceutical Pentapeptide · Topical Anti-Aging

TopicalRoute

5-AALength (KTTKS)Gomes 2022

Collagen I/IIIPrimary targetPaccola 2025

Topical · Dermal · Twice Daily

VIP

Neuropeptide · VPAC1/VPAC2 Agonist · Emergency Use Authorization (COVID-19 ARDS)

IntravenousPrimary routeBrown 2023

ARDSLead indicationUdupa 2025

Phase 3Development stage

IV infusion · Inhaled (investigational)Brown 2023 Boesing 2022

01Mechanism of Action

Parameter

Matrixyl

VIP

Primary target

Dermal fibroblastsPaccola 2025

VPAC1 and VPAC2 G-protein-coupled receptorsUdupa 2025

Pathway

Fibroblast stimulation → Collagen I/III/IV synthesis → Glycosaminoglycan deposition → ECM remodeling

VIP → VPAC1/VPAC2 activation → cAMP elevation → Pulmonary vasodilation + epithelial protection

Downstream effect

Enhanced extracellular matrix synthesis, improved dermal density, collagen remodelingPaccola 2025

Anti-inflammatory cytokine modulation, alveolar-capillary membrane stabilization, pulmonary smooth muscle relaxation, reduced neutrophil infiltration

Feedback intact?

—

Yes — exogenous VIP acts as physiological agonist

Origin

Synthetic pentapeptide KTTKS derived from pro-collagen I fragment, N-palmitoylated for lipophilicityGomes 2022

Endogenous 28-amino-acid neuropeptide; synthetic analogue (aviptadil) identical to natural VIP

Antibody development

—

02Dosage Protocols

Parameter

Matrixyl

VIP

Formulation concentration

0.5–5% in topical vehicle

Common cosmeceutical range; higher concentrations in clinical formulations.

—

Application frequency

Twice daily (AM/PM)

Standard cosmeceutical protocol.

—

Duration

8–12 weeks minimum for visible effect

Collagen synthesis requires sustained application.

—

In vitro evidence

Fibroblast viability + ECM gene upregulationPaccola 2025

—

Vehicle

Serum, cream, or emulsion base

Lipophilic carriers enhance penetration.

—

Intravenous (ARDS protocol)

—

60–90 mcg/kg/day via continuous infusion

TESICO trial protocol for COVID-19 ARDS.

Infusion duration

—

12-hour continuous IV infusion dailyBrown 2023

Inhaled (investigational)

—

Variable dosing under clinical trial protocolsBoesing 2022

Delivered via nebulizer for direct pulmonary deposition.

Treatment duration

—

3–14 days (acute ARDS)

Evidence basis

—

Phase 3 RCT (TESICO)Brown 2023

816-patient randomized controlled trial in COVID-19 ARDS.

Reconstitution

—

Lyophilized powder reconstituted with sterile diluent per protocol

Half-life

—

~2 minutes (plasma)

Rapid clearance necessitates continuous infusion.

04Side Effects & Safety

Parameter

Matrixyl

VIP

Irritation

Mild erythema, pruritus in sensitive skin (rare)

—

Allergic reaction

Contact dermatitis (uncommon)

—

Systemic absorption

Negligible — topical application only

—

Hypotension

—

Transient vasodilation-related blood pressure drop

Tachycardia

—

Reflex tachycardia secondary to vasodilation

Infusion site reactions

—

Erythema, phlebitis (IV administration)

GI symptoms

—

Nausea, diarrhea (VIP is endogenous GI peptide)

Overall tolerability

—

Well-tolerated in Phase 3 trials; adverse event profile comparable to placebo

Absolute Contraindications

Matrixyl

·Known hypersensitivity to palmitoyl peptides

VIP

·Known hypersensitivity to aviptadil or formulation components

Relative Contraindications

Matrixyl

·Active dermatitis or open wounds at application site

VIP

·Severe hypotension or shock states (monitor blood pressure)
·Pregnancy — insufficient safety data

05Administration Protocol

Parameter

Matrixyl

VIP

1. Cleanse

Wash face with gentle cleanser. Pat dry.

Reconstitute lyophilized aviptadil powder with sterile diluent per manufacturer protocol. Inspect solution for particulates — should be clear and colorless.

2. Application

Apply 2–3 drops to fingertips. Massage gently into target areas (face, neck, décolletage). Allow 1–2 minutes for absorption.

Administer as continuous 12-hour intravenous infusion via central or peripheral line. Use infusion pump for precise dosing (60–90 mcg/kg/day divided over infusion duration).

3. Timing

Twice daily — morning and evening. Apply before heavier creams or sunscreen.

Monitor blood pressure, heart rate, and oxygenation continuously during first infusion. Assess for hypotension and adjust infusion rate if needed.

4. Storage

Store at room temperature, away from direct sunlight. Stable in formulation for 12–24 months.

Deliver via jet or mesh nebulizer per clinical trial protocol. Patient seated upright, normal tidal breathing for 10–15 minutes.

5. Storage

—

Store lyophilized powder at 2–8 °C, light-protected. Reconstituted solution: use immediately or within 24 hours if refrigerated.

06Stack Synergy

Matrixyl

+ GHK-Cu

Multi-pathway

View GHK-Cu →

Matrixyl (Pal-KTTKS) stimulates fibroblast collagen synthesis via pro-collagen I mimicry, while GHK-Cu acts as a copper-binding tripeptide that enhances ECM remodeling through metalloproteinase modulation and wound healing pathways. Combined, they address collagen synthesis (Matrixyl) and matrix remodeling/repair (GHK-Cu) through distinct mechanisms, producing complementary effects on dermal architecture.

Matrixyl: 0.5–5% topical serum · AM/PM
GHK-Cu: 1–2% topical serum · same application
Frequency: Twice daily
Primary benefit: Enhanced collagen synthesis + ECM remodeling, improved skin density and elasticity

VIP

— no documented stacks